ReviewIranian journal of pharmaceutical research : IJPR
Chinese Herbal Medicine in the Treatment of Chronic Kidney Disease: A Narrative Review of Mechanisms and Therapeutic Potential.
Review in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- pH-Responsive Carboxymethyl Cellulose-Encapsulating Hesperidin-Selenium Nanoparticles Attenuate Paracetamol-Induced Acute Kidney Injury via Keap-1/Nrf2, NF-κB, and Mitochondrial Apoptosis Modulation.International journal of molecular sciences · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Chronic kidney disease (CKD) is a significant global health issue, characterized by its progressive nature and the limited effectiveness of conventional treatments. Chinese herbal medicine (CHM) has been used for centuries in East Asia to manage CKD by targeting key pathological processes. This review focuses on synthesizing evidence from various studies to explore the potential role of CHM in managing CKD, particularly through classical formulations, individual herbs, and their bioactive compounds with known nephroprotective effects. Evidence Acquisition: The review synthesizes evidence from preclinical studies, randomized controlled trials (RCTs), and meta-analyses to assess the effectiveness of CHM in CKD management. It highlights the use of classical CHM formulations like Liuwei Dihuang decoction, Zhenwu decoction, Shen-Qi-Wan (SQW), and Yu-Quan Wan (YQW), which are based on CHM theory and syndrome differentiation. Additionally, individual herbs such as Results: Integration of CHM with standard therapy has shown promising results in improving renal function and reducing proteinuria, especially in patients with CKD and IgA nephropathy (IgAN). Evidence supports the multi-mechanistic actions of CHM, including the potential for its anti-inflammatory, anti-fibrotic, antioxidant, and immunomodulatory effects to positively impact CKD progression. Conclusions: Despite the growing body of evidence supporting the therapeutic value of CHM in CKD management, challenges still exist, such as the standardization of herbal preparations, ensuring safety, and gaining regulatory approval. For CHM to be more broadly integrated into evidence-based nephrology practice, further high-quality clinical research and harmonization of regulatory frameworks will be crucial. Overall, CHM offers a complementary approach to CKD treatment that aligns with classical principles and multi-targeted actions, contributing to a broader global strategy for CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.